Sandra K. Johnston

ORCID: 0000-0003-4106-3924
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glioma Diagnosis and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • Mathematical Biology Tumor Growth
  • Brain Metastases and Treatment
  • Meningioma and schwannoma management
  • Musculoskeletal pain and rehabilitation
  • Medical Imaging and Analysis
  • Brain Tumor Detection and Classification
  • MRI in cancer diagnosis
  • Cancer, Hypoxia, and Metabolism
  • Spine and Intervertebral Disc Pathology
  • Cancer Treatment and Pharmacology
  • Cancer Research and Treatments
  • Radiopharmaceutical Chemistry and Applications
  • Bone health and osteoporosis research
  • Opioid Use Disorder Treatment
  • Medical Imaging Techniques and Applications
  • Neuroblastoma Research and Treatments
  • Lymphoma Diagnosis and Treatment
  • Sleep and Wakefulness Research
  • Cancer Genomics and Diagnostics
  • CAR-T cell therapy research
  • Hip and Femur Fractures
  • Cardiac pacing and defibrillation studies
  • Sleep and related disorders

University of Washington
2016-2025

Seattle University
2009-2022

Kaiser Permanente
2021

VA Puget Sound Health Care System
2021

Mayo Clinic in Arizona
2018-2020

Mayo Clinic in Florida
2016-2020

Neurological Surgery
2010-2020

Mayo Clinic Hospital
2017-2020

Columbia University Irving Medical Center
2017-2020

Washington University in St. Louis
2020

Object Malignant gliomas are incurable, primary brain neoplasms noted for their potential to extensively invade parenchyma. Current methods of clinical imaging do not elucidate the full extent invasion, making it difficult predict which, if any, patients likely benefit from gross total resection. Our goal was apply a mathematical modeling approach estimate overall tumor invasiveness on patient-by-patient basis and determine whether resection would improve survival in with relatively less...

10.1371/journal.pone.0099057 article EN cc-by PLoS ONE 2014-10-28

We conducted a prospective Phase II study of high-dose methotrexate (HD-MTX) and rituximab with deferred whole brain radiotherapy in patients newly diagnosed B-cell primary central nervous system lymphoma objective evaluating progression-free survival (PFS).Forty (25 men; 15 women), ages 18 -93 years (median 61.5), were treated.All received biweekly HD-MTX/rituximab (8 g/ m 2 /dose; 375 mg/m /dose) for 4-6 cycles (induction) following best radiographic response, every 4 weeks HD-MTX g/m...

10.1093/neuonc/noq011 article EN Neuro-Oncology 2010-02-08

BACKGROUND. Temozolomide (TMZ) is one of the most potent chemotherapy agents for treatment glioblastoma. Unfortunately, almost half glioblastoma tumors are TMZ resistant due to overexpression methylguanine methyltransferase (MGMThi). Coadministration O6-benzylguanine (O6BG) can restore sensitivity, but causes off-target myelosuppression. Here, we conducted a prospective clinical trial test whether gene therapy confer O6BG resistance in hematopoietic stem cells (HSCs) improves tolerance and outcome.

10.1172/jci76739 article EN Journal of Clinical Investigation 2014-08-07

Glioblastomas with a specific mutation in the isocitrate dehydrogenase 1 (IDH1) gene have better prognosis than gliomas wild-type IDH1. Here we compare IDH1 mutational status 172 contrast-enhancing glioma patients invasion profile generated by patient-specific mathematical model developed based on MR imaging. We show that IDH1-mutated were relatively more invasive for all as well subset of 158 histologically confirmed glioblastomas. The appearance this increased, model-predicted appears to...

10.1093/neuonc/nou027 article EN Neuro-Oncology 2014-05-15

Abstract Objective To examine the effectiveness of cognitive‐behavioral and pharmacologic treatment depression in rheumatoid arthritis (RA). Methods Subjects (n = 54) with confirmed diagnoses both major RA were randomly assigned to 1 3 groups: 1) cognitive‐behavioral/pharmacologic group (CB‐PHARM), 2) attention‐control/pharmacologic group, or 3) control group. Measures depression, psychosocial status, health pain, disease activity collected at baseline, posttreatment (10 weeks), 6‐month...

10.1002/art.11459 article EN Arthritis Care & Research 2003-12-08

A retrospective evaluation of single agent bevacizumab was carried out in adults with recurrent alkylator-refractory 1p19q codeleted anaplastic oligodendrogliomas (AO) an objective determining progression-free survival (PFS). There is no standard therapy for alkylator-resistant AO, and hence a need exists new therapies.Twenty-two patients aged 24 to 60 years AO were treated. All had previously been treated surgery, radiotherapy, adjuvant chemotherapy (temozolomide, 17; carmustine wafers, 4;...

10.1002/cncr.24179 article EN Cancer 2009-02-07

The prognostic significance of Karnofsky performance status in neoplastic meningitis (NM) has not been demonstrated patient groups similarly matched for known variables.To determine the effect on survival NM.Retrospective comparison.A university tertiary medical center.Two well-matched cohorts with cytologically positive NM (n = 30; group A) and without B) independence activities daily living as defined by a score 70 or greater less than 70, respectively.Groups were age, primary tumor, site...

10.1001/archneurol.2008.506 article EN Archives of Neurology 2009-01-01

Standard-of-care multiparameter magnetic resonance imaging (MRI) scans of the brain were used to objectively subdivide glioblastoma multiforme (GBM) tumors into regions that correspond variations in blood flow, interstitial edema, and cellular density. We hypothesized distribution these distinct tumor ecological “habitats” at time presentation will impact course disease. retrospectively analyzed initial MRI 2 groups patients diagnosed with GBM, a long-term survival group comprising subjects...

10.18383/j.tom.2018.00052 article EN cc-by Tomography 2019-03-01

Glioblastomas, lethal primary brain tumors, are known for their heterogeneity and invasiveness. A growing body of literature has been developed demonstrating the clinical relevance a biomathematical model, proliferation-invasion glioblastoma growth. Of interest here is development treatment response metric, days gained (DG). This metric based on individual tumor kinetics estimated through segmented volumes hyperintense regions T1-weighted gadolinium-enhanced T2-weighted magnetic resonance...

10.1200/cci.18.00066 article EN cc-by-nc-nd JCO Clinical Cancer Informatics 2019-02-13

Glioblastomas are aggressive primary brain tumors known for their inter- and intratumor heterogeneity. This disease is uniformly fatal, with heterogeneity the major reason treatment failure recurrence. Just like nature vs nurture debate, can arise from intrinsic or environmental influences. Whilst it impossible to clinically separate observed behavior of cells context, using a mathematical framework combined multiscale data gives us insight into relative roles variation different sources. To...

10.1371/journal.pcbi.1007672 article EN cc-by PLoS Computational Biology 2020-02-26

To the authors' knowledge, there currently is no standard therapy for platinum-resistant ependymoma; hence, a need exists new therapies. In current study, retrospective evaluation of temozolomide (TMZ) in adults with recurrent, supratentorial, platinum-refractory, World Health Organization grade 2 ependymoma was performed, an objective determining 6-month progression-free survival (PFS).A total 25 patients, ages 28 to 63 years, recurrent were treated. All patients had previously been treated...

10.1002/cncr.24524 article EN Cancer 2009-06-30

Abstract Background Sex is recognized as a significant determinant of outcome among glioblastoma patients, but the relative prognostic importance features has not been thoroughly explored for sex differences. Methods Combining multi-modal MR images, biomathematical models, and patient clinical information, this investigation assesses which pretreatment variables have sex-specific impact on survival patients (299 males 195 females). Results Among males, tumor (T1Gd) radius was predictor...

10.1186/s12885-020-06816-2 article EN cc-by BMC Cancer 2020-05-19

Background Chronic low back pain (CLBP) and fibromyalgia (FM) are leading causes of suffering, disability, social costs. Current pharmacological treatments do not target molecular mechanisms driving CLBP FM, no validated biomarkers available, hampering the development effective therapeutics. Omics research has potential to substantially advance our ability develop mechanism-specific therapeutics by identifying pathways involved in pathophysiology facilitate diagnostic, predictive, prognostic...

10.1371/journal.pone.0312061 article EN cc-by PLoS ONE 2025-04-16

Despite the intra- and intertumoral heterogeneity seen in glioblastoma multiforme (GBM), there is little definitive data on underlying cause of differences patient survivals. Serial imaging assessment tumor growth allows quantification kinetics (TGK) measured terms changes velocity radial expansion imaging. Because a systematic study this entire TGK phenotype-growth before treatment during each to recurrence -has never been coordinately studied GBMs, we sought identify whether patients...

10.1200/cci.17.00080 article EN JCO Clinical Cancer Informatics 2018-03-01

Abstract Given the negative impact of opioid use on population health, prescriptions for alternative pain-relieving medications, including gabapentin, have increased. We wanted to determine whether people who filled gabapentin and concurrently (“gabapentin + opioids”) had greater mortality than those an active control medication (tricyclic antidepressants [TCAs] or duloxetine) opioids (“TCAs/duloxetine opioids”). In this population-based, propensity score-matched cohort study, we identified...

10.1097/j.pain.0000000000003448 article EN Pain 2024-10-11
Coming Soon ...